Literature DB >> 7307591

Improved lung compliance following indomethacin therapy in premature infants with persistent ductus arteriosus.

T F Yeh, A Thalji, L Luken, L Lilien, I Carr, R S Pildes.   

Abstract

In the course of a double-blind controlled study of intravenous indomethacin therapy in premature infants with patent ducts arteriosus (PDA), dynamic lung compliance (CL) was determined in 11 infants (six control, five indomethacin) who were not on assisted ventilation during the study period. The clinical, biochemical and laboratory data before the study were comparable between the groups. Following therapy with indomethacin there was a significant decrease in left atrial/aortic root ratio (LA/Ao), left ventricular end-diastolic dimension (LVEDD) on echocardiogram, and an increase in tidal volume (VT) and CL. In the control group, these variables did not change significantly. The improved lung compliance following early indomethacin closure of PDA may alter the clinical course and outcome of these premature infants.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7307591     DOI: 10.1378/chest.80.6.698

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

Review 1.  The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasia.

Authors:  Ronald I Clyman
Journal:  Semin Perinatol       Date:  2013-04       Impact factor: 3.300

2.  Pulmonary compliance in sick low birthweight infants. How reliable is the measurement of oesophageal pressure?

Authors:  A Thomson; J Elliott; M Silverman
Journal:  Arch Dis Child       Date:  1983-11       Impact factor: 3.791

Review 3.  Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants.

Authors:  Peter W Fowlie; Peter G Davis; William McGuire
Journal:  Cochrane Database Syst Rev       Date:  2010-07-07

4.  Is surgical ligation of patent ductus arteriosus necessary? The Western Australian experience of conservative management.

Authors:  J M Brooks; J N Travadi; S K Patole; D A Doherty; K Simmer
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-05       Impact factor: 5.747

5.  Patent ductus arteriosus ligation alters pulmonary gene expression in preterm baboons.

Authors:  Nahid Waleh; Donald C McCurnin; Bradley A Yoder; Philip W Shaul; Ronald I Clyman
Journal:  Pediatr Res       Date:  2011-03       Impact factor: 3.756

Review 6.  Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all?

Authors:  Ronald I Clyman; James Couto; Gail M Murphy
Journal:  Semin Perinatol       Date:  2012-04       Impact factor: 3.300

Review 7.  The pharmacology of neonatal resuscitation and cardiopulmonary intensive care. Part II--Extended intensive care.

Authors:  W E Benitz; L R Frankel; D K Stevenson
Journal:  West J Med       Date:  1986-07

8.  Pulmonary effects of closure of patent ductus arteriosus in premature infants with severe respiratory distress syndrome.

Authors:  T Farstad; D Bratlid
Journal:  Eur J Pediatr       Date:  1994-12       Impact factor: 3.183

9.  The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial.

Authors:  Ronald Clyman; George Cassady; James K Kirklin; Monica Collins; Joseph B Philips
Journal:  J Pediatr       Date:  2009-03-25       Impact factor: 4.406

10.  Indomethacin for symptomatic patent ductus arteriosus in preterm infants.

Authors:  Peter Evans; Deirdre O'Reilly; Jonathan N Flyer; Roger Soll; Souvik Mitra
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.